New research just presented at #GI25: BREAKWATER study finds 1L EC + mFOLFOX6 improves outcomes in BRAFV600E-mutant mCRC, offering new SOC: brnw.ch/21wQfxm
#ASCODailyNews #GICSM
#ASCODailyNews #GICSM
January 25, 2025 at 10:29 PM
New research just presented at #GI25: BREAKWATER study finds 1L EC + mFOLFOX6 improves outcomes in BRAFV600E-mutant mCRC, offering new SOC: brnw.ch/21wQfxm
#ASCODailyNews #GICSM
#ASCODailyNews #GICSM
#OncSky #MedSky
Another subcutaneous #ImmunoOnc therapy (nivo) now officially in the toolkit 👇
#melsm #lcsm #kcsm #blcsm #gicsm #stcsm #esocsm
www.fda.gov/drugs/resour...
Another subcutaneous #ImmunoOnc therapy (nivo) now officially in the toolkit 👇
#melsm #lcsm #kcsm #blcsm #gicsm #stcsm #esocsm
www.fda.gov/drugs/resour...
FDA approves nivolumab and hyaluronidase-nvhy for subcutaneous injecti
FDA approves nivolumab and hyaluronidase-nvhy for subcutaneous injection
www.fda.gov
December 28, 2024 at 3:20 AM
#colon #cancer screening simplified, courtesy NCCN
For general population, multiple guidelines suggest starting screening at 45-50y. Even though it's a literal pain in the @ss, colonoscopy remains standard of care till fecal/blood tests gain prominence.
#gicsm #gastrointestinal #oncosky #oncsky
For general population, multiple guidelines suggest starting screening at 45-50y. Even though it's a literal pain in the @ss, colonoscopy remains standard of care till fecal/blood tests gain prominence.
#gicsm #gastrointestinal #oncosky #oncsky
November 23, 2024 at 3:44 AM
New research just presented at #GI25: STARTER-NET trial shows everolimus + lanreotide more than doubles PFS vs everolimus monotherapy among pts w/ aggressive GEP-NETs: brnw.ch/21wQeCg
#ASCODailyNews #GICSM
#ASCODailyNews #GICSM
January 24, 2025 at 9:33 PM
New research just presented at #GI25: STARTER-NET trial shows everolimus + lanreotide more than doubles PFS vs everolimus monotherapy among pts w/ aggressive GEP-NETs: brnw.ch/21wQeCg
#ASCODailyNews #GICSM
#ASCODailyNews #GICSM
More news from #ASCO25 Plenary! MATTERHORN results: Perioperative durvalumab/FLOT shows superior EFS over placebo/FLOT in early-stage, resectable G/GEJ cancer: brnw.ch/21wT4R8
#ASCODailyNews #GICSM
#ASCODailyNews #GICSM
June 1, 2025 at 8:41 PM
More news from #ASCO25 Plenary! MATTERHORN results: Perioperative durvalumab/FLOT shows superior EFS over placebo/FLOT in early-stage, resectable G/GEJ cancer: brnw.ch/21wT4R8
#ASCODailyNews #GICSM
#ASCODailyNews #GICSM
Dr. Emil Lou breaks down exciting new data re: resectable gastric/gastroesophageal junction cancer in our latest Science in Seconds. Learn more: meetings.asco.org/abstracts-pr...
#gicsm #esosm
#gicsm #esosm
June 1, 2025 at 8:36 PM
Dr. Emil Lou breaks down exciting new data re: resectable gastric/gastroesophageal junction cancer in our latest Science in Seconds. Learn more: meetings.asco.org/abstracts-pr...
#gicsm #esosm
#gicsm #esosm
Standing room only in the breakout session on “Optimizing Management of Liver Tumors in the Setting of Liver Dysfunction: Balancing Tumor Control With Hepatotoxicity” breakout session happening now at #GI26:
meetings.asco.org/meetings/202... #gicsm
meetings.asco.org/meetings/202... #gicsm
January 9, 2026 at 6:56 PM
Standing room only in the breakout session on “Optimizing Management of Liver Tumors in the Setting of Liver Dysfunction: Balancing Tumor Control With Hepatotoxicity” breakout session happening now at #GI26:
meetings.asco.org/meetings/202... #gicsm
meetings.asco.org/meetings/202... #gicsm
Updated results from the BREAKWATER trial support encorafenib plus cetuximab and mFOLFOX6 as a new standard of care for patients with BRAF V600E-mutated mCRC, Dr Elena Elez of @vhio.bsky.social said at #ASCO25. #gicsm #crcsm shorturl.at/4CoQl
Combo Deemed New Standard of Care for BRAF-Mutant, Metastatic Colorectal Cancer
Encorafenib plus cetuximab and mFOLFOX6 outperformed standard first-line chemotherapy in patients with BRAF V600E-mutated, metastatic colorectal cancer.
shorturl.at
May 30, 2025 at 10:16 PM
Updated results from the BREAKWATER trial support encorafenib plus cetuximab and mFOLFOX6 as a new standard of care for patients with BRAF V600E-mutated mCRC, Dr Elena Elez of @vhio.bsky.social said at #ASCO25. #gicsm #crcsm shorturl.at/4CoQl
🚨 Happening Soon: @mskcancercenter.bsky.social's Eileen O'Reilly and @mayocliniccancer.bsky.social's Tanios Bekaii-Saab will kick off #ISGIO2025! Join them for opening remarks as program chairs at 9 a.m. CDT/10 a.m. EDT. #GICSM
See the agenda for a full lineup of MSK experts: bit.ly/3JSTg6V
See the agenda for a full lineup of MSK experts: bit.ly/3JSTg6V
September 12, 2025 at 1:07 PM
🚨 Happening Soon: @mskcancercenter.bsky.social's Eileen O'Reilly and @mayocliniccancer.bsky.social's Tanios Bekaii-Saab will kick off #ISGIO2025! Join them for opening remarks as program chairs at 9 a.m. CDT/10 a.m. EDT. #GICSM
See the agenda for a full lineup of MSK experts: bit.ly/3JSTg6V
See the agenda for a full lineup of MSK experts: bit.ly/3JSTg6V
Study S2303 is for people who are seeking further treatment for advanced #stomach or #esophageal #cancer. It tests adding an #immunotherapy drug (#nivolumab) to usual treatment. SWOG.org/S2303. 1-800-4-CANCER. #esocsm #stcsm #gicsm #gastriccancer
February 14, 2025 at 5:42 PM
Study S2303 is for people who are seeking further treatment for advanced #stomach or #esophageal #cancer. It tests adding an #immunotherapy drug (#nivolumab) to usual treatment. SWOG.org/S2303. 1-800-4-CANCER. #esocsm #stcsm #gicsm #gastriccancer
Abstract 4008: GAIN (bit.ly/4jpQKkm) Neoadjuvant/perioperative gemcitabine plus cisplatin improved R0 resection rates and OS vs direct surgery in patients with biliary tract cancer. #ASCO25 #gicsm
Program Guide – ASCO Meeting Program Guide
bit.ly
May 29, 2025 at 1:40 PM
Abstract 4008: GAIN (bit.ly/4jpQKkm) Neoadjuvant/perioperative gemcitabine plus cisplatin improved R0 resection rates and OS vs direct surgery in patients with biliary tract cancer. #ASCO25 #gicsm
As the sun sets in San Francisco and #GI26 comes to a close, we reflect with gratitude on the 3 days we spent with all of you, in person and online. Three full days of learning and connecting, making progress on treatments and care for patients with GI cancers. #gicsm
asco.org/gi-program
asco.org/gi-program
January 11, 2026 at 12:44 AM
As the sun sets in San Francisco and #GI26 comes to a close, we reflect with gratitude on the 3 days we spent with all of you, in person and online. Three full days of learning and connecting, making progress on treatments and care for patients with GI cancers. #gicsm
asco.org/gi-program
asco.org/gi-program
FDA Approves Zanidatamab for Biliary Tract Cancers With High HER2 Levels @mskcancercenter.bsky.social #OncSky #bileductcancer #HER2 #gicsm www.mskcc.org/news/fda-app...?
FDA Approves Zanidatamab for Biliary Tract Cancers With High HER2 Levels
Learn more about a new treatment for biliary tract cancers with high levels of HER2. The drug zanidatamab has been approved by the FDA, thanks to a clinical trial co-led by MSK.
www.mskcc.org
November 26, 2024 at 2:10 AM
FDA Approves Zanidatamab for Biliary Tract Cancers With High HER2 Levels @mskcancercenter.bsky.social #OncSky #bileductcancer #HER2 #gicsm www.mskcc.org/news/fda-app...?
Adding perioperative systemic therapy to CRS-HIPEC improved PFS and DFS in patients with resectable colorectal peritoneal metastases in the CAIRO6 trial. Results were presented at #ASCO25 by Dr Ignace De Hingh of Catharina Cancer Institute. #gicsm shorturl.at/b48yX
May 31, 2025 at 2:31 PM
Adding perioperative systemic therapy to CRS-HIPEC improved PFS and DFS in patients with resectable colorectal peritoneal metastases in the CAIRO6 trial. Results were presented at #ASCO25 by Dr Ignace De Hingh of Catharina Cancer Institute. #gicsm shorturl.at/b48yX
Top 10 Gastrointestinal Cancer Abstracts From #ASCO25. Brought to you by Dr Suneel Kamath from @clevelandclinic.bsky.social. #gicsm
May 29, 2025 at 1:40 PM
Top 10 Gastrointestinal Cancer Abstracts From #ASCO25. Brought to you by Dr Suneel Kamath from @clevelandclinic.bsky.social. #gicsm
Enrolling: #PARAMUNE @SWOG S2303 ph 2/3 randomized #clinicaltrial of paclitaxel + ramucirumab w/wo nivolumab in patients w advanced MSS, HER2- #gastric, #GEJ, or #esophageal #adenocarcinoma w PD-L1 CPS ≥ 1.
SWOG.org/clinical-trials/S2303
PI: Anwaar Saeed, MD @upmchillmancc.bsky.social #esocsm #gicsm
SWOG.org/clinical-trials/S2303
PI: Anwaar Saeed, MD @upmchillmancc.bsky.social #esocsm #gicsm
January 2, 2025 at 3:56 PM
Enrolling: #PARAMUNE @SWOG S2303 ph 2/3 randomized #clinicaltrial of paclitaxel + ramucirumab w/wo nivolumab in patients w advanced MSS, HER2- #gastric, #GEJ, or #esophageal #adenocarcinoma w PD-L1 CPS ≥ 1.
SWOG.org/clinical-trials/S2303
PI: Anwaar Saeed, MD @upmchillmancc.bsky.social #esocsm #gicsm
SWOG.org/clinical-trials/S2303
PI: Anwaar Saeed, MD @upmchillmancc.bsky.social #esocsm #gicsm
Physical activity, particularly at a consistent level in line with guideline recommendations, significantly reduces both risk of and mortality from digestive system #cancers. Published in @jamaoncology.com.
https://bit.ly/3WDdULm
#gicancer #gicsm
https://bit.ly/3WDdULm
#gicancer #gicsm
Consistent Physical Activity Reduces Risk of Digestive System Cancers, Research Suggests
Alongside reducing body mass index, “physical activity may have systematic anticancer effect, such as improving insulin sensitivity, reducing hyperinsulinemia, lowering systemic inflammation, and enhancing immune function,” researchers reported.
bit.ly
November 9, 2025 at 6:42 PM
Physical activity, particularly at a consistent level in line with guideline recommendations, significantly reduces both risk of and mortality from digestive system #cancers. Published in @jamaoncology.com.
https://bit.ly/3WDdULm
#gicancer #gicsm
https://bit.ly/3WDdULm
#gicancer #gicsm
‼️ #ASCO26 simultaneous publication by Bekaii-Saab et al:
Pemigatinib for Unresectable or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor-2 Rearrangement: Results From the Phase 3 FIGHT-302 Trial
Read the full article: https://bit.ly/3PF33Rd
#gicsm
Pemigatinib for Unresectable or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor-2 Rearrangement: Results From the Phase 3 FIGHT-302 Trial
Read the full article: https://bit.ly/3PF33Rd
#gicsm
June 1, 2026 at 6:15 PM
‼️ #ASCO26 simultaneous publication by Bekaii-Saab et al:
Pemigatinib for Unresectable or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor-2 Rearrangement: Results From the Phase 3 FIGHT-302 Trial
Read the full article: https://bit.ly/3PF33Rd
#gicsm
Pemigatinib for Unresectable or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor-2 Rearrangement: Results From the Phase 3 FIGHT-302 Trial
Read the full article: https://bit.ly/3PF33Rd
#gicsm
Escalating adjuvant treatment based on ctDNA positivity does not improve RFS in patients with stage III colon cancer, according to research presented at #ASCO25 by Dr Jeanne Tie of @petermaccc.bsky.social. #gicsm shorturl.at/ZnaFK
June 1, 2025 at 3:13 AM
Escalating adjuvant treatment based on ctDNA positivity does not improve RFS in patients with stage III colon cancer, according to research presented at #ASCO25 by Dr Jeanne Tie of @petermaccc.bsky.social. #gicsm shorturl.at/ZnaFK
Long preoperative chemo elicited more pathologic complete responses than short preoperative chemo in PDAC, but no difference in EFS was seen. Presented at #ESMO25 by Dr Michele Reni of San Raffaele Scientific Institute. #gicsm #pancsm #esmo2025
shorturl.at/cPimQ
shorturl.at/cPimQ
October 20, 2025 at 5:57 PM
Long preoperative chemo elicited more pathologic complete responses than short preoperative chemo in PDAC, but no difference in EFS was seen. Presented at #ESMO25 by Dr Michele Reni of San Raffaele Scientific Institute. #gicsm #pancsm #esmo2025
shorturl.at/cPimQ
shorturl.at/cPimQ
Abstract 3505: CAIRO6 (bit.ly/4kx25Qw). Adding perioperative systemic therapy to CRS-HIPEC did not improve OS in patients with resectable colorectal peritoneal metastases. #ASCO25 #gicsm
Program Guide – ASCO Meeting Program Guide
bit.ly
May 29, 2025 at 1:40 PM
Abstract 3505: CAIRO6 (bit.ly/4kx25Qw). Adding perioperative systemic therapy to CRS-HIPEC did not improve OS in patients with resectable colorectal peritoneal metastases. #ASCO25 #gicsm
#Cancerdeaths have increased by more than 70% globally over the last 3 decades and are estimated to continue to climb, with more than 18 million cancer deaths projected in 2050. These findings were published in @thelancetoncol.bsky.social.
https://bit.ly/42Htid9
#lcsm #gicsm #bcsm
https://bit.ly/42Htid9
#lcsm #gicsm #bcsm
Researchers Estimate More Than 18 Million Cancer Deaths Worldwide in 2050
Overall, 41.7% of cancer deaths in 2023 were attributed to potentially modifiable risk factors, with behavioral risk factors having the greatest impact.
bit.ly
October 1, 2025 at 4:20 PM
#Cancerdeaths have increased by more than 70% globally over the last 3 decades and are estimated to continue to climb, with more than 18 million cancer deaths projected in 2050. These findings were published in @thelancetoncol.bsky.social.
https://bit.ly/42Htid9
#lcsm #gicsm #bcsm
https://bit.ly/42Htid9
#lcsm #gicsm #bcsm
Abstracts for #GI26 now available! Discover emerging treatment modalities, the latest clinical trial results, advances in precision medicine, and more—all in the field of gastrointestinal cancers. #gicsm #OncTwitter
View the abstracts: brnw.ch/21wYQVs
View the abstracts: brnw.ch/21wYQVs
January 5, 2026 at 10:38 PM
Abstracts for #GI26 now available! Discover emerging treatment modalities, the latest clinical trial results, advances in precision medicine, and more—all in the field of gastrointestinal cancers. #gicsm #OncTwitter
View the abstracts: brnw.ch/21wYQVs
View the abstracts: brnw.ch/21wYQVs
Abstract 3507 (bit.ly/4mAT5vz). The combination of olomorasib and cetuximab demonstrated activity in this phase 1/2 study of patients with KRAS G12C-mutant colorectal cancer. #ASCO25 #gicsm
Program Guide – ASCO Meeting Program Guide
bit.ly
May 29, 2025 at 1:40 PM
Abstract 3507 (bit.ly/4mAT5vz). The combination of olomorasib and cetuximab demonstrated activity in this phase 1/2 study of patients with KRAS G12C-mutant colorectal cancer. #ASCO25 #gicsm